
Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism


SUPPLEMENTARY MATERIAL

Supplementary figure S1. Intragenic mosaic mutations identified by Ion AmpliSeq-Ion PGM sequencing. (A) *De novo* mosaic frameshift mutation in *NIPBL* (c.[=/7373_7374del] p.[=/(Ser2458Cysfs*4)] identified in individual II:1 (Family 3059) in 12% of reads in two saliva-derived DNA samples. The sequence data appeared normal in two blood-derived DNA samples from the same case. (B) Mosaic missense mutation in *NIPBL* (c.[=/6893G>A] p.[=/(Arg2298His)]) identified in individual II:1 (Family 4407) at approximately 15% and 38% in blood-derived and saliva-derived DNA samples, respectively. (C) *De novo* mosaic inframe deletion of 3 bp in *SMC1A* (c.[=/1585_1587del] p.[=/(Lys529del)]) identified at significantly different levels (53% and 10%) in two saliva-derived DNA samples from individual II:1 (Family 3176) collected at ages of 14.3 and 18.3 years, respectively. Mutations are marked by blue blocks along the sequence reads. Sequence traces were obtained from NextGENe software v.2.3.3 (Soft Genetics).


Family 3059 (NIPBL c.[=/7373_7374del] p.[=/(Ser2458Cysfs*4)] de novo)




Family 4407 (*NIPBL* c.[=/6893G>A] p.[=/(Arg2298His)])




Family 3176 (*SMC1A* c.[=/1585_1587del] p.[=/(Lys529del)] *de novo*)




Supplementary figure S2. Genome-wide array CGH analysis of mutation-negative cases. (A) *De novo* heterozygous deletion of 1.3Mb is marked along chromosome 1 (red arrow) in data analysed in Pat ID 3076 (arr 1p36.33 (984,137-2,284,140; hg19)). The results show absence of the deletion in both parents (Fam ID 3076). (B) Heterozygous duplication of 520 kb is marked (blue arrow) on array CGH data from chromosome 12 in Pat ID 3040 (arr 12q13.13 (53,582,733-54,102,733; hg19)). Black dots represent the segmented probes along each chromosome. Log₂ ratio (case:control) is shown on the y-axis and the genomic context is represented along the x-axis using the software programme Signal Map (Roche Nimblegen). (C) The duplication of *ESPL1* was confirmed using a TaqMan CNV assay and compared to seven control samples with either known intragenic causative mutations in another gene (C1-C3) or normal *ESPL1* copy number based on whole-exome data (C4-C7). Genomic copy number, calculated as 2^{ΔΔCt}, is shown on the y-axis. Analysis was carried out in triplicate using the software Copy Caller v1.0 (Applied Biosystems).








Supplementary figure S3. Developmental milestones for individuals with mutations in *NIPBL*, *SMC1A*, *SMC3*, *HDAC8*, *RAD21*, *ANKRD11*, CNV, and for those without a mutation identified. Ages at which each developmental milestone was reached is shown on the y-axis in months. The number of cases with available growth data in each genotype category is shown at the bottom of each box-plot. The width of each box-plot is proportional to the number of cases in each category. The line in the middle of each box is the median. The bottom and top of each box represent the 25th and 75th centiles, respectively. The whiskers represent the 95th centile (if normally distributed) or the minimum/maximum data points. Outlier values are shown by circles.



Supplementary figure S4. Box-plots of pre- and post-natal growth for each of the gene categories (*NIPBL*, *SMC1A*, *SMC3*, *HDAC8* and *RAD21*), chromosomal rearrangements (CNV) and those without an identifiable mutation (no_mutation). Box-plots are coloured in red for prenatal growth and purple for postnatal growth. Z scores were calculated using the British Growth Survey data, adjusted for sex and age. The number of cases in each category is shown below the box-plot. BL, birth length; Ht, height; BWt, birth weight; Wt, weight; BOFC, head circumference at birth; OFC, head circumference.







Supplementary table S1. Type and number of mutations identified in a cohort of 163 affected individuals from whom DNA was available (including mosaic mutations)

| Gene and mutation type | Number of mutations (%) | | |
|------------------------|-------------------------|------------|--|
| NIPBL | | | |
| | Nonsense | 12 (7.4%) | |
| | Frameshift | 9 (5.5%) | |
| | Splice site | 8 (4.9%) | |
| | Missense* | 16 (9.8%) | |
| | Genomic loss/gain | 1 (0.6%)† | |
| | Total | 46 (28.2%) | |
| SMC1A | | | |
| | Nonsense | - | |
| | Frameshift | - | |
| | Splice site | - | |
| | Missense* | 5 (3.1%) | |
| | Genomic loss/gain | - | |
| | Total | 5 (3.1%) | |
| SMC3 | | | |
| | Nonsense | 1 (0.6%) | |
| | Frameshift | - | |
| | Splice site | - | |
| | Missense* | 4 (2.5%) | |
| | Genomic loss/gain | - | |
| | Total | 5 (3.1%) | |
| HDAC8 | | | |
| | Nonsense | - | |
| | Frameshift | - | |
| | Splice site | - | |
| | Missense* | 3 (1.8%)§ | |
| | Genomic loss/gain | 3 (1.8%)§ | |
| | Total | 6 (3.6%) | |
| RAD21 | | | |
| | Nonsense | - | |
| | Frameshift | - | |
| | Splice site | 1 (0.6%) | |
| | Missense* | - | |
| | Genomic loss/gain | - | |
| | Total | 1 (0.6%) | |

^{*} Includes in-frame insertion/deletions

[†] Murray et al. (2012)

[§] Kaiser et al. (2014)

Supplementary table S2. Summary of whole-exome sequencing results from five unrelated CdLS and CdLS-like cases

| Patient ID | 3060 | 3061 | 3051 | 3041 | 3024 |
|-----------------------------|---------|-----------------|---------|------------------|---------|
| Mean depth | 260X | 276X | 252X | 237X | 283X |
| Reads on target | 53% | 49% | 51% | 67% | 47% |
| Total number of SNVs (% in | 2346262 | 2710305 | 2434134 | 1116837 | 2432647 |
| dbSNP131) | (91%) | (91%) | (91%) | (86%) | (91%) |
| Total number of indels (% | 103260 | 140495 | 108481 | 44526 | 102501 |
| in dbSNP131) | (14%) | (14%) | (14%) | (12%) | (14%) |
| Filtered* non-synonymous | | | | | |
| coding | 1146 | 1105 | 1072 | 1566 | 924 |
| Filtered* stop gained | 59 | 50 [¥] | 54 | 73 | 53 |
| Filtered* frameshift coding | 665 | 679 | 627 | 683 [∞] | 427 |
| Filtered* essential splice | | | | | |
| site | 14 | 16 | 24 | 33 | 18 |

^{*} Not in dbSNP131, 1000 Genomes Pilot projects 1,2,3 or release 2010-08-04, 8 HapMap exomes, or 10 Kabuki syndrome exomes;

¥ contains the mosaic NIPBL nonsense mutation, c.[=/1435C>T] p.[=/(Arg479*)];

SNV, single nucleotide variant; indel, insertion/deletion

[∞] Contains the *ANKRD11* c.6210_211del p.(Lys2070Asnfs*31) frameshift mutation;

Supplementary table S3. Genotype-phenotype correlations in unrelated cases of CdLS

| | | Z score birth length* [95% C.I.] | Z score birth weight* [95% C.I.] | Z score birth head circumference* | Z score height* | Z score weight* | Z score head circumference* | Mean Gestalt score† | Mean Severity score |
|-------------|-------------|-------------------------------------|-------------------------------------|--------------------------------------|-------------------|-------------------|--------------------------------|---------------------|---------------------|
| | | (N) | (N) | [95% C.I.] (N) | [95% C.I.] (N) | [95% C.I.] (N) | [95% C.I.] (<i>N</i>) | [95% C.I.] (N) | [95% C.I.] (N) |
| | | -2.59 [-5.72 to | -2.32 [-2.76 to - | -3.88 [-5.53 to - | -3.68 [-4.45 to - | -3.91 [-4.67 to - | -5.14 [-5.74 to - | 7.42 [6.77 to | 19.63 [16.85 to |
| NIPBL (all) | | 0.55] (4) | 1.88] (38) | 2.23] (4) | 2.91] (23) | 3.15] (27) | 4.53] (27) | 8.08] (28) | 22.41] (34) |
| | nonsense/fr | | -2.43 [-3.31 to - | | -4.52 [-6.36 to - | -4.39 [-5.93 to - | -5.86 [-6.69 to - | 7.71 [6.79 to | 20.79 [16.54 to |
| | ameshift | - | 1.54] (17) | -3.07 [NA] (1) | 2.68] (7) | 2.84] (10) | 5.04] (10) | 8.63] (11) | 25.03] (16) |
| | | | -3.21 [-4.14 to - | | -3.99 [-6.09 to - | -3.88 [-6.63 to - | -5.27 [-7.64 to - | 8.39 [7.15 to | 23.56 [14.26 to |
| | splice site | -4.93 [NA] (1) | 2.27] (6) | -5.30 [NA] (1) | 1.90] (5) | 1.13] (6) | 2.89] (6) | 9.63] (6) | 32.85] (7) |
| | | -1.80 [-5.44 to | -1.88 [-2.27 to - | -3.58 [-9.04 to 1.88] | -3.29 [-4.19 to - | -3.49 [-4.35 to - | -4.39 [-5.24 to - | 6.70 [5.27 to | 15.80 [12.39 to |
| | Missense | 1.83] (3) | 1.48] (14) | (2) | 2.38] (10) | 2.64] (11) | 3.53] (10) | 8.13] (10) | 19.21] (10) |
| | Genomic | | | | | | | | |
| | loss/gain | - | -1.33 [NA] (1) | - | -0.06 [NA] (1) | - | -4.57 [NA] (1) | 5.67 [NA] (1) | 12.00 [NA] (1) |
| | | | -1.23 [-2.08 to - | | -1.79 [-3.28 to - | 0.30 [-2.61 to | -3.56 [-13.31 to | 4.72 [2.37 to | 13.88 [8.79 to |
| SMC1A | | - | 0.38] (4) | -2.36 [NA] (1) | 0.31] (3) | 3.21] (3) | 6.19] (3) | 7.08] (3) | 18.97] (5) |
| | | | | | -2.41 [-3.89 to - | -2.10 [-4.33 to | -4.02 [-7.54 to - | 5.20 [2.13 to | |
| SMC3 | | - | -1.04 [NA] (1) | - | 0.92] (5) | 0.13] (5) | 0.49] (5) | 8.27] (5) | 10.70 [NA] (1) |
| | | -2.04 [-6.11 to | -2.65 [-4.94 to - | -2.87 [-4.62 to - | -2.71 [-3.46 to - | -1.82 [-3.09 to - | -3.52 [-5.01 to - | 5.20 [2.88 to | 18.37 [14.43 to |
| HDAC8 | | 2.03] (2) | 0.35] (4) | 1.12] (3) | 1.96] (6) | 0.53] (5) | 2.02] (6) | 7.52] (5) | 22.32] (4) |
| RAD21 | | - | = | - | -0.97 [NA] (1) | -1.83 [NA] (1) | -4.71 [NA] (1) | - | - |
| | | | -1.56 [-20.37 to | | -1.15 [-4.62 to | -0.18 [-3.22 to | -0.68 [-3.13 to | 4.78 [2.87 to | 15.20 [5.03 to |
| ANKRD11 | | - | 17.25] (2) | - | 2.32] (3) | 2.87] (3) | 1.76] (3) | 6.69] (3) | 25.36] (2) |
| Genomic | | | | | | | | | |
| rearrangem | | | | | | | | | |
| ents | | -1.19 [NA] (1) | -2.07 [NA] (1) | - | -2.29 [NA] (1) | -0.41 [NA] (1) | -2.90 [NA] (1) | 5.67 [NA] (1) | 24.00 [NA] (1) |
| No | | -3.33 [-16.86 to | -2.02 [-2.46 to - | -3.51 [-4.57 to - | -2.37 [-2.72 to - | -2.18 [-2.78 to - | -3.63 [-4.17 to - | 5.63 [5.11 to | 17.73 [15.84 to |
| mutation | | 10.21] (2) | 1.57] (58) | 2.46] (8) | 2.02] (56) | 1.58] (55) | 3.10] (57) | 6.15] (53) | 19.63] (48) |

^{*} Z scores obtained using the British Growth Survey data; N, number of individuals; C.I., confidence interval of the mean; NA, not applicable

Supplementary table S4. Structural anomalies in individuals with an identified mutation.

| System | Gene | Mutation type | Details |
|------------------------|-------|------------------|--|
| Cardiac | NIPBL | Splice | PFO; pulmonary valve stenosis |
| | | Truncating | PFO |
| | | Truncating | pulmonary artery stenosis |
| | | Truncating | ASD; VSD |
| | | Truncating | ASD; VSD; PDA |
| | | Truncating | ASD; VSD |
| | HDAC8 | | ASD; VSD |
| | | | ASD |
| | SMC1A | | bicuspid aortic valve |
| Limb reduction defects | NIPBL | Splice | phocomelia right arm; micromelia left arm with one digit missing |
| | | Splice | |
| | | Truncating | absent ulna; left hand has thumb and index finger only |
| | | Truncating | right single digit; left four digits; single bone in right forearm |
| | | Truncating | |
| | | Truncating | |
| | | Missense | bilateral thumb hypoplasia |
| Gastrointestinal | NIPBL | Missense | tracheoesophageal fistula |
| | | Splice | pyloric stenosis |
| | | Truncating | pyloric stenosis |
| | | Truncating | malrotation |
| | SMC3 | | volvulus on two occasions |
| Ocular | NIPBL | Truncating | myopia -2 dioptres |
| | | Truncating | cataract |
| | I | 1 | 1 |

PFO = patent foramen ovale, ASD = atrial septal defect, VSD = ventricular septal defect, PDA = patent ductus arteriosus.